![Page Background](./../common/page-substrates/page0163.jpg)
Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
MS-88
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
291. Dowsett M, Cuzick J, Howell A, Jackson I. Pharmacokinetics of
anastrozole and tamoxifen alone, and in combination, during adjuvant
endocrine therapy for early breast cancer in postmenopausal women: a
sub-protocol of the 'Arimidex and tamoxifen alone or in combination'
(ATAC) trial. Br J Cancer 2001;85:317-324. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/11487258.
292. Buzdar AU, Guastalla JP, Nabholtz JM, et al. Impact of
chemotherapy regimens prior to endocrine therapy: Results from the
ATAC (anastrozole and tamoxifen, alone or in combination) trial. Cancer
2006;107:472-480. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/16804925.
293. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular
adverse events during adjuvant endocrine therapy for early breast
cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J
Clin Oncol 2007;25:5715-5722. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/17998546.
294. Rabaglio M, Sun Z, Price KN, et al. Bone fractures among
postmenopausal patients with endocrine-responsive early breast cancer
treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann
Oncol 2009;20:1489-1498. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/19474112.
295. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole
therapy alone or in sequence with tamoxifen in women with breast
cancer. N Engl J Med 2009;361:766-776. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/19692688.
296. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to
anastrozole versus continued tamoxifen treatment of early breast
cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J
Clin Oncol 2005;23:5138-5147. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/16009955.
297. Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to
anastrozole versus continued tamoxifen treatment of early breast
cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
Ann Oncol 2006;17 Suppl 7:10-14. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/16760270.
298. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of
exemestane after two to three years of tamoxifen therapy in
postmenopausal women with primary breast cancer. N Engl J Med
2004;350:1081-1092. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/15014181.
299. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal
women with endocrine-responsive early breast cancer to anastrozole
after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8
and ARNO 95 trial. Lancet 2005;366:455-462. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/16084253.
300. Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching
from adjuvant tamoxifen to anastrozole in postmenopausal women with
hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet
Oncol 2006;7:991-996. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/17138220.
301. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen
and exemestane in early breast cancer (TEAM): a randomised phase 3
trial. Lancet 2011;377:321-331. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/21247627.
302. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole
in postmenopausal women after five years of tamoxifen therapy for
early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
Available at:
http://www.ncbi.nlm.nih.gov/pubmed/14551341.
303. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant
treatment with letrozole improves outcome in women with early-stage
breast cancer who complete 5 years of tamoxifen. J Clin Oncol
2008;26:1948-1955. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/18332475.